Brown Advisory’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.43M | Sell |
32,222
-2,330
| -7% | -$346K | 0.01% | 533 |
|
|
2026
Q1 | $4.55M | Sell |
34,552
-190,736
| -85% | -$25.3M | 0.01% | 546 |
|
|
2025
Q4 | $32M | Sell |
225,288
-243,259
| -52% | -$35.2M | 0.04% | 260 |
|
|
2025
Q3 | $65.8M | Sell |
468,547
-130,672
| -22% | -$17.7M | 0.09% | 166 |
|
|
2025
Q2 | $75.3M | Sell |
599,219
-296,323
| -33% | -$34M | 0.1% | 144 |
|
|
2025
Q1 | $99M | Sell |
895,542
-2,751
| -0.3% | -$348K | 0.14% | 119 |
|
|
2024
Q4 | $123M | Sell |
898,293
-43,854
| -5% | -$5.42M | 0.16% | 115 |
|
|
2024
Q3 | $109M | Sell |
942,147
-53,067
| -5% | -$7.27M | 0.14% | 119 |
|
|
2024
Q2 | $137M | Sell |
995,214
-93,119
| -9% | -$12.8M | 0.18% | 98 |
|
|
2024
Q1 | $150M | Sell |
1,088,333
-25,080
| -2% | -$3.43M | 0.2% | 95 |
|
|
2023
Q4 | $147M | Buy |
1,113,413
+23,831
| +2% | +$2.74M | 0.21% | 92 |
|
|
2023
Q3 | $123M | Sell |
1,089,582
-10,274
| -0.9% | -$1.08M | 0.2% | 97 |
|
|
2023
Q2 | $104M | Buy |
1,099,856
+20,963
| +2% | +$2.05M | 0.16% | 117 |
|
|
2023
Q1 | $109M | Buy |
1,078,893
+17,232
| +2% | +$1.79M | 0.18% | 110 |
|
|
2022
Q4 | $127M | Sell |
1,061,661
-13,265
| -1% | -$1.55M | 0.24% | 98 |
|
|
2022
Q3 | $114M | Buy |
1,074,926
+5,140
| +0.5% | +$522K | 0.22% | 95 |
|
|
2022
Q2 | $104M | Buy |
1,069,786
+61,036
| +6% | +$5.63M | 0.2% | 106 |
|
|
2022
Q1 | $94.6M | Buy |
1,008,750
+72,266
| +8% | +$6.12M | 0.14% | 125 |
|
|
2021
Q4 | $79.8M | Buy |
936,484
+143,477
| +18% | +$13.2M | 0.1% | 148 |
|
|
2021
Q3 | $76.1M | Buy |
793,007
+14,661
| +2% | +$1.38M | 0.11% | 149 |
|
|
2021
Q2 | $75.7M | Buy |
778,346
+13,887
| +2% | +$1.33M | 0.11% | 157 |
|
|
2021
Q1 | $74.3M | Buy |
764,459
+66,729
| +10% | +$7M | 0.13% | 138 |
|
|
2020
Q4 | $66.9M | Buy |
697,730
+54,588
| +8% | +$5.27M | 0.12% | 137 |
|
|
2020
Q3 | $61.8M | Buy |
643,142
+17,707
| +3% | +$2.05M | 0.13% | 123 |
|
|
2020
Q2 | $76.3M | Buy |
625,435
+20,960
| +3% | +$2.32M | 0.18% | 103 |
|
|
2020
Q1 | $52.3M | Buy |
604,475
+41,489
| +7% | +$4.06M | 0.16% | 112 |
|
|
2019
Q4 | $60.5M | Buy |
562,986
+3,473
| +0.6% | +$364K | 0.15% | 126 |
|
|
2019
Q3 | $50.4M | Buy |
559,513
+25,268
| +5% | +$2.36M | 0.14% | 135 |
|
|
2019
Q2 | $45.1M | Buy |
534,245
+158,858
| +42% | +$13M | 0.13% | 152 |
|
|
2019
Q1 | $33.1M | Buy |
375,387
+66,036
| +21% | +$5.52M | 0.09% | 186 |
|
|
2018
Q4 | $22.1M | Sell |
309,351
-4,578
| -1% | -$439K | 0.07% | 227 |
|
|
2018
Q3 | $38.6M | Buy |
313,929
+10,903
| +4% | +$1.24M | 0.11% | 173 |
|
|
2018
Q2 | $29.8M | Buy |
303,026
+20,733
| +7% | +$1.86M | 0.09% | 197 |
|
|
2018
Q1 | $23.4M | Buy |
282,293
+4,996
| +2% | +$422K | 0.08% | 214 |
|
|
2017
Q4 | $21.5M | Buy |
277,297
+4,025
| +1% | +$275K | 0.07% | 226 |
|
|
2017
Q3 | $16.7M | Buy |
273,272
+25,115
| +10% | +$1.33M | 0.06% | 245 |
|
|
2017
Q2 | $11.4M | Buy |
248,157
+6,160
| +3% | +$299K | 0.03% | 292 |
|
|
2017
Q1 | $10.5M | Sell |
241,997
-137,614
| -36% | -$5.9M | 0.04% | 286 |
|
|
2016
Q4 | $14.7M | Buy |
379,611
+32,341
| +9% | +$1.46M | 0.05% | 248 |
|
|
2016
Q3 | $17.6M | Buy |
347,270
+25,957
| +8% | +$1.29M | 0.06% | 219 |
|
|
2016
Q2 | $14.6M | Buy |
321,313
+11,824
| +4% | +$544K | 0.05% | 237 |
|
|
2016
Q1 | $12.2M | Buy |
309,489
+81,033
| +35% | +$3.22M | 0.04% | 245 |
|
|
2015
Q4 | $12.9M | Buy |
228,456
+74,902
| +49% | +$3.81M | 0.04% | 236 |
|
|
2015
Q3 | $6.11M | Buy |
+153,554
| New | +$7.42M | 0.02% | 329 |
|
Other funds holding NBIX
Brown Advisory's NBIX Position: Q2 2026 in Review
Brown Advisory reduced its Neurocrine Biosciences (NBIX) stake by 6.7% in Q2 2026, selling an estimated $346K and leaving 32,222 shares worth $5.43M. The position accounts for 0.01% of the portfolio, ranked #533.
Brown Advisory first reported a position in NBIX in Q3 2015 and has held it in 44 quarters since. The position peaked at $150M in Q1 2024. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Brown Advisory held 32,222 shares of Neurocrine Biosciences worth $5.43M as of Q2 2026.
- Brown Advisory sold 2,330 Neurocrine Biosciences shares in Q2 2026, an estimated $346K.
- Neurocrine Biosciences made up 0.01% of Brown Advisory's portfolio in Q2 2026, its #533 holding.
- Brown Advisory first reported a position in Neurocrine Biosciences in Q3 2015 and has held it in 44 quarters since.
- Brown Advisory's Neurocrine Biosciences position peaked at $150M in Q1 2024.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.